

Bart Barlogie

List of Publications by Citations

Source: <https://exaly.com/author-pdf/534076/bart-barlogie-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

253
papers

6,880
citations

37
h-index

82
g-index

256
ext. papers

7,662
ext. citations

3.7
avg, IF

5.02
L-index

#	Paper	IF	Citations
253	Thalidomide and hematopoietic-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , 2006 , 354, 1021-30	59.2	621
252	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 519-527	40	496
251	Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. <i>Blood</i> , 2001 , 98, 492-4	2.2	474
250	Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. <i>Blood</i> , 1997 , 89, 789-793	2.2	468
249	Treatment of multiple myeloma. <i>Blood</i> , 2004 , 103, 20-32	2.2	365
248	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. <i>British Journal of Haematology</i> , 2007 , 138, 176-85	4.5	262
247	Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations. <i>Blood</i> , 1998 , 92, 2908-2913	2.2	215
246	Results of autologous stem cell transplant in multiple myeloma patients with renal failure. <i>British Journal of Haematology</i> , 2001 , 114, 822-9	4.5	212
245	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 333-42	21.7	206
244	Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. <i>Blood</i> , 2008 , 112, 3115-21	2.2	198
243	Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. <i>Blood</i> , 2010 , 115, 4168-73	2.2	175
242	Curing myeloma at last: defining criteria and providing the evidence. <i>Blood</i> , 2014 , 124, 3043-51	2.2	167
241	Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. <i>British Journal of Haematology</i> , 2001 , 114, 600-7	4.5	165
240	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. <i>British Journal of Haematology</i> , 2006 , 135, 158-64	4.5	144
239	Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. <i>British Journal of Haematology</i> , 1996 , 95, 349-53	4.5	130
238	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. <i>Blood</i> , 2016 , 128, 1735-44	2.2	129
237	Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1209-14	2.2	125

236	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. <i>Blood</i> , 2006 , 107, 2633-8	2.2	118
235	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2039-2051	4.7	114
234	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014 , 124, 1404-11	2.2	107
233	Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. <i>Cancer</i> , 2008 , 113, 355-9	6.4	107
232	Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. <i>Blood</i> , 2015 , 126, 2475-8	2.2	85
231	Anti-myeloma activity of pamidronate in vivo. <i>British Journal of Haematology</i> , 1998 , 103, 530-2	4.5	83
230	Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. <i>Blood</i> , 2008 , 112, 3122-5	2.2	79
229	High-dose therapy and immunomodulatory drugs in multiple myeloma. <i>Seminars in Oncology</i> , 2002 , 29, 26-33	5.5	77
228	Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. <i>British Journal of Haematology</i> , 2001 , 112, 167-74	4.5	69
227	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. <i>Cancer Cell</i> , 2016 , 29, 639-652	24.3	67
226	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016 , 127, 1896-906	2.2	65
225	Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. <i>Blood</i> , 2008 , 111, 94-100	2.2	59
224	Assessment of Total Lesion Glycolysis by F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 1981-1987	12.9	57
223	The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. <i>Clinical Cancer Research</i> , 2016 , 22, 5783-5794	12.9	56
222	Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. <i>BMC Bioinformatics</i> , 2015 , 16, 63	3.6	48
221	The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma. <i>Haematologica</i> , 2017 , 102, e364-e367	6.6	44
220	Recombinant human erythropoietin and the anemia of multiple myeloma. <i>Stem Cells</i> , 1993 , 11, 88-94	5.8	40
219	Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232.. <i>Blood</i> , 2007 , 110, 77-77	2.2	40

218	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. <i>Blood</i> , 2015 , 126, 25-25	2.2	39
217	Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 211-4	2	38
216	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. <i>Blood</i> , 2016 , 128, 2919-2930	2.2	36
215	The future of autologous stem cell transplantation in myeloma. <i>Blood</i> , 2014 , 124, 328-33	2.2	35
214	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). <i>Haematologica</i> , 2015 , 100, 1214-21	6.6	34
213	Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3023-7	2.2	32
212	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. <i>Blood</i> , 2015 , 125, 3756-9	2.2	31
211	Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. <i>Cell Division</i> , 2006 , 1, 23	2.8	30
210	Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. <i>Seminars in Hematology</i> , 2003 , 40, 33-8	4	30
209	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018 , 103, 1047-1053	6.6	29
208	Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. <i>Nature Communications</i> , 2016 , 7, 10290	17.4	26
207	The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. <i>International Journal of Hematology</i> , 2011 , 94, 321-333	2.3	24
206	Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. <i>British Journal of Haematology</i> , 2001 , 112, 776-82	4.5	24
205	Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 1480-1480	2.2	24
204	CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. <i>Blood</i> , 2014 , 124, 2051-60	2.2	23
203	Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 96, 768-770	2.2	23
202	Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. <i>Annals of Hematology</i> , 2011 , 90, 423-8	3	22
201	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. <i>Blood Advances</i> , 2018 , 2, 1470-1479	7.8	22

200	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. <i>Haematologica</i> , 2017 , 102, e313-e316	6.6	21
199	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. <i>American Journal of Hematology</i> , 2017 , 92, 739-745	7.1	21
198	Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma. <i>Cancer</i> , 2001 , 91, 900-908	6.4	19
197	Bortezomib (Velcade) + Adriamycin + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 2399-2399	2.2	19
196	The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. <i>Oncotarget</i> , 2017 , 8, 27854-27867	3.3	19
195	and Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 2422-2432	12.9	17
194	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018 , 24, 2913-2919	12.9	17
193	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. <i>Blood Cancer Journal</i> , 2019 , 9, 62	7	17
192	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. <i>Blood Cancer Journal</i> , 2020 , 10, 70	7	16
191	Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. <i>Lancet Haematology</i> , 2017 , 4, e443-e451	14.6	16
190	Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.. <i>Blood</i> , 2004 , 104, 77-77	2.2	16
189	Hematopoietic stem cell transplants for multiple myeloma. <i>Leukemia and Lymphoma</i> , 1996 , 22, 25-36	1.9	15
188	Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. <i>Cancer</i> , 2008 , 112, 2720-5	6.4	12
187	Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. <i>British Journal of Haematology</i> , 2019 , 184, 578-593	4.5	11
186	Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 469-74		10
185	Addition of Bortezomib (Velcade) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 929-929	2.2	10
184	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. <i>PLoS Medicine</i> , 2020 , 17, e1003323	11.6	10
183	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	10

182	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. <i>Clinical Cancer Research</i> , 2017 , 23, 2665-2672	12.9	9
181	Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. <i>BMC Cancer</i> , 2015 , 15, 864	4.8	9
180	Could CR mean cure?. <i>Blood</i> , 2011 , 118, 483	2.2	8
179	Complete response in myeloma: a Trojan horse?. <i>Blood</i> , 2006 , 108, 2134-2134	2.2	8
178	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. <i>Theranostics</i> , 2019 , 9, 4756-4763	12.1	7
177	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. <i>Blood</i> , 2016 , 128, 4431-4431	2.2	7
176	Identification of Novel Transcriptional Consequences of Activation and Inactivation of TP53 in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 393-393	2.2	7
175	Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent thrombocytopenia. <i>American Journal of Hematology</i> , 1994 , 47, 203-7	7.1	6
174	The effect of novel therapies in high-molecular-risk multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 870-879	0.6	6
173	A common genetic variant in 19q13B is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3. <i>British Journal of Haematology</i> , 2016 , 174, 991-3	4.5	6
172	Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 692-701	5	5
171	Protective Effect of VELCADE [®] on Thalidomide-Associated Deep Vein Thrombosis (DVT).. <i>Blood</i> , 2004 , 104, 4914-4914	2.2	5
170	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.. <i>Blood</i> , 2005 , 106, 423-423	2.2	5
169	Identification of Three Novel Chromosomal Translocation Partners Involving the Immunoglobulin Loci in Newly Diagnosed Myeloma and Human Myeloma Cell Lines.. <i>Blood</i> , 2005 , 106, 1552-1552	2.2	4
168	Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients. <i>Blood</i> , 2008 , 112, 667-667	2.2	4
167	Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B. <i>Blood</i> , 2010 , 116, 368-368	2.2	4
166	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. <i>Blood</i> , 2014 , 124, 4775-4775	4.75	4
165	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. <i>Blood</i> , 2015 , 126, 20-20	2.2	4

164	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. <i>Blood Advances</i> , 2019 , 3, 3962-3967	7.8	4
163	Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis?. <i>International Journal of Cardiology</i> , 2014 , 172, 265-6	3.2	3
162	Waldenström's macroglobulinemia. <i>Current Treatment Options in Oncology</i> , 2000 , 1, 97-103	5.4	3
161	Management of Patients with Multiple Myeloma (MM) Failing Total Therapy 2 (TT 2) According to Thalidomide (THAL) Randomization.. <i>Blood</i> , 2004 , 104, 1483-1483	2.2	3
160	FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls.. <i>Blood</i> , 2004 , 104, 2473-2473	2.2	3
159	A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.. <i>Blood</i> , 2006 , 108, 111-111	2.2	3
158	Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4). <i>Blood</i> , 2014 , 124, 1199-1199	2.2	3
157	Curing Multiple Myeloma (MM) with Total Therapy (TT). <i>Blood</i> , 2014 , 124, 195-195	2.2	3
156	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. <i>Blood</i> , 2014 , 124, 3418-3418	2.2	3
155	Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019 , 25, 201-209	12.9	3
154	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	3
153	Using a latent class model to refine risk stratification in multiple myeloma. <i>Statistics in Medicine</i> , 2015 , 34, 2971-80	2.3	2
152	Going with the flow, and beyond, in myeloma. <i>Blood</i> , 2008 , 112, 3917-8	2.2	2
151	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. <i>Blood</i> , 2019 , 134, 4333-4333 ²	2.2	2
150	A Complete Remission (CR) Is Not a Prerequisite for Prolonged Survival after Autotransplants for Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 926-926	2.2	2
149	Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).. <i>Blood</i> , 2005 , 106, 3490-3490	2.2	2
148	The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.. <i>Blood</i> , 2005 , 106, 510-510	2	2
147	Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.. <i>Blood</i> , 2007 , 110, 548-548	2.2	2

146	Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2012 , 120, 4083-4083	2.2	2
145	Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012 , 120, 579-579	2.2	2
144	Validation of a Predictive Formula for Collection of Hematopoietic Progenitor Cells (HPC) By Leukapheresis at 2 Institutions Using 4 Different Machine Protocols. <i>Blood</i> , 2014 , 124, 2458-2458	2.2	2
143	Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience. <i>Blood</i> , 2014 , 124, 2999-2999	2.2	2
142	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. <i>Blood</i> , 2015 , 126, 2979-2979	2	2
141	Specific Exosomal microRNA Are Differentially Expressed Between High and Low-Risk Myeloma Suggesting They Are Pathogenically Important. <i>Blood</i> , 2015 , 126, 4189-4189	2.2	2
140	Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials. <i>Blood</i> , 2016 , 128, 1192-1192	2.2	2
139	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. <i>Blood</i> , 2016 , 128, 3278-3278	2.2	2
138	Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients. <i>Blood</i> , 2016 , 128, 3304-3304	2.2	2
137	High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. <i>British Journal of Haematology</i> , 2021 , 195, 283-286	4.5	2
136	Walking on myeloma. <i>Blood</i> , 2018 , 132, 1724	2.2	2
135	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e734-e751	2	1
134	Drug Combinations with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017 , 377, 91-259.	2	1
133	Multiple Myeloma and Chronic Lymphocytic Leukemia: Commonalities and Differences in Biology and Therapy. <i>Leukemia and Lymphoma</i> , 1991 , 5 Suppl 1, 27-32	1.9	1
132	The Gene Expression Signatures (GEP) of Whole Bone Marrow Biopsies (Bx) from Patients with Multiple Myeloma (MM) in Remission Reflect Disease Risk and Therapy.. <i>Blood</i> , 2005 , 106, 1547-1547	2.2	1
131	Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 3392-3392	2.2	1
130	SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.. <i>Blood</i> , 2005 , 106, 3488-3488	2.2	1
129	Gene Expression Profiling (GEP) of Purified Plasma Cells at Baseline and 48hr after-Dexamethasone (D) or Thalidomide (T) Improve Outcome Prediction of Baseline GEP Alone in Patients with Multiple Myeloma (MM) Treated with Total Therapy 2 (TT2).. <i>Blood</i> , 2005 , 106, 502-502	2.2	1

128	A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.. <i>Blood</i> , 2006 , 108, 3393-3393	2.2	1
127	A Gene Expression-Based Risk Stratification Model Developed in Newly Diagnosed Multiple Myeloma Treated with High Dose Therapy Is Predictive of Outcome in Relapsed Disease Treated with Single Agent Bortezomib.. <i>Blood</i> , 2007 , 110, 656-656	2.2	1
126	Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.. <i>Blood</i> , 2009 , 114, 744-744	2.2	1
125	Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts. <i>Blood</i> , 2011 , 118, 808-808	2.2	1
124	Hyperhaploid Multiple Myeloma (MM): A Rare Karyotypic Subgroup Retaining Disomy 18 and 1q12~23 Amplification. <i>Blood</i> , 2012 , 120, 3983-3983	2.2	1
123	The Antimalarial Agent Artesunate Exerts Its Antimyeloma Activity By Affecting The Mitochondria and The Reactive Oxygen Status Of The Myeloma Cells and Its Efficacy Depends On Intracellular Bivalent Iron Levels. <i>Blood</i> , 2013 , 122, 4444-4444	2.2	1
122	Modified Combat Removes Batch Effects from Myeloma Cell GEP-derived Risk Scores and Molecular Subgroup Assignment. <i>Blood</i> , 2014 , 124, 3355-3355	2.2	1
121	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. <i>Blood</i> , 2014 , 124, 3409-3409	2.2	1
120	Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 725-725	2.2	1
119	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. <i>Blood</i> , 2015 , 126, 1806-1806	2.2	1
118	Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. <i>Blood</i> , 2015 , 126, 1808-1808	2.2	1
117	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). <i>Blood</i> , 2015 , 126, 1843-1843	2.2	1
116	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. <i>Blood</i> , 2015 , 126, 369-369	2.2	1
115	The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. <i>Blood</i> , 2015 , 126, 372-372	2.2	1
114	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. <i>Blood</i> , 2016 , 128, 2065-2065	2.2	1
113	The 70-Gene MyPRSR prognostic Risk Score Signature Predicts Increased Risk of Progression from MGUS to Multiple Myeloma Requiring Treatment. <i>Blood</i> , 2016 , 128, 3275-3275	2.2	1
112	Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2016 , 128, 373-373	2.2	1
111	Use of Multiple Myeloma 70-Gene Prognostic Risk Score As a Continuous Predictor of Patient Outcome. <i>Blood</i> , 2016 , 128, 5614-5614	2.2	1

110	Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. <i>Blood</i> , 2016 , 128, 802-802	2.2	1
109	The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2004 , 104, 1159-1159	2.2	1
108	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. <i>Blood</i> , 2019 , 134, 3309-3309	2.2	1
107	Identification of Biomarkers Associated with MAF-Mediated Resistance to Proteasome Inhibitors in t(14;16) Multiple Myeloma. <i>Blood</i> , 2015 , 126, 3020-3020	2.2	1
106	Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy. <i>Blood</i> , 2008 , 112, 733-733	2.2	1
105	A 15 Hour Dosing-Collection Interval for Plerixafor Is at Least as Effective as the Standard 10 Hour Interval.. <i>Blood</i> , 2009 , 114, 2152-2152	2.2	1
104	Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma. <i>Blood</i> , 2011 , 118, 2918-2918	2.2	1
103	MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 281-281	2.2	1
102	Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival. <i>Blood</i> , 2013 , 122, 1911-1911	2.2	1
101	Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro. <i>Blood</i> , 2013 , 122, 1926-1926	2.2	1
100	Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	1
99	The role of transplant in multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2005 , 3, 604-606	2.2	1
98	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e341-e344	2	0
97	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2014 , 124, 2128-2128	2.2	0
96	Bortezomib Down-Regulates HLA Class I and Enhances Natural Killer Cell Mediated Lysis of Myeloma.. <i>Blood</i> , 2006 , 108, 3498-3498	2.2	0
95	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. <i>Blood</i> , 2016 , 128, 3285-3285	2.2	0
94	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. <i>Blood</i> , 2016 , 128, 4416-4416	2.2	0
93	Muscular Relapse in a Patient With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015 , 33, e125-9	2.2	0

92	Reply to J.C. Regelink et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e744-e745	2.2
91	Meeting summary. <i>Stem Cells</i> , 1996 , 13, 164-165	5.8
90	28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 13-13	2.2
89	N-Cadherin Stabilizes E-Catenin and Promotes E-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1572-1572	2.2
88	Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).. <i>Blood</i> , 2004 , 104, 940-940	2.2
87	NY-ESO-1 Specific T-Cells Are Spontaneously Present in High-Risk Myeloma and Kill Primary Myeloma Cells.. <i>Blood</i> , 2004 , 104, 2454-2454	2.2
86	Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).. <i>Blood</i> , 2004 , 104, 1158-1158	2.2
85	Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.. <i>Blood</i> , 2004 , 104, 934-934	2.2
84	Generation of Tumor-Specific Cytotoxic T Lymphocytes in Multiple Myeloma Using Dendritic Cells Pulsed with Tumor-Derived Heat Shock Protein gp96.. <i>Blood</i> , 2004 , 104, 2451-2451	2.2
83	Tumor Antigen Immunization of Sibling Stem Cell Transplant Donors in Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 3340-3340	2.2
82	Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 4935-4935	2.2
81	NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.. <i>Blood</i> , 2004 , 104, 2464-2464	2.2
80	Myeloma Cell-Derived Factors Retard the Differentiation and Function of Dendritic Cells.. <i>Blood</i> , 2004 , 104, 2447-2447	2.2
79	Gene Expression Profiling (GEP) in Multiple Myeloma (MM): Comparison of Purified MM Cells (PMM), Random Bone Marrow Biopsies (RBX) and Fine Needle Biopsies from Focal Lesions (FNBX).. <i>Blood</i> , 2005 , 106, 1535-1535	2.2
78	Serum Concentrations of Vitamin B-12 and Alkaline Phosphatase in Newly Diagnosed Multiple Myeloma Patients.. <i>Blood</i> , 2005 , 106, 5110-5110	2.2
77	The Ellipticine Derivative NSC 338258 Has Anti-Myeloma Activity.. <i>Blood</i> , 2005 , 106, 3379-3379	2.2
76	Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.. <i>Blood</i> , 2005 , 106, 506-506	2.2
75	Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.. <i>Blood</i> , 2005 , 106, 1152-1152	2.2

74	Total Therapy 1 (TT1): Status Report of the First Tandem Autotransplant (TAT) Trial for Multiple Myeloma (MM) - 15 Years Later.. <i>Blood</i> , 2005 , 106, 1151-1151	2.2
73	Beta-Catenin and N-Cadherin in Myeloma: Implications for Adhesion and Migration.. <i>Blood</i> , 2005 , 106, 2497-2497	2.2
72	Acquired Resistance to Activated Protein C (aAPCR) Is Associated with Increased Risk of Deep Vein Thrombosis in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3484-3484	2.2
71	Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.. <i>Blood</i> , 2005 , 106, 5116-5116	2.2
70	The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.. <i>Blood</i> , 2005 , 106, 1157-1157	2.2
69	Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs Discontinuous Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 1153-1153	2.2
68	AMD3100 Plus G-CSF Mobilizes the Majority of Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), and Hodgkin Disease (HD) Patients Who Failed Prior Mobilization with Other Regimens.. <i>Blood</i> , 2006 , 108, 5218-5218	2.2
67	DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation.. <i>Blood</i> , 2006 , 108, 3392-3392	2.2
66	SNP Associations with Event Free Survival in Myeloma from Two Phase III Clinical Trials Using the Bank On A Cure Chip.. <i>Blood</i> , 2006 , 108, 131-131	2.2
65	Immune Reconstruction Inflammatory Syndrome (IRIS) with Invasive Aspergillosis (IA) in Patients (pts) with Hematological Cancer (Hem-Ca): Clinical and Research Implications.. <i>Blood</i> , 2006 , 108, 5313-5313	2.2
64	JNK Regulates DKK1 Expression in Multiple Myeloma Cells.. <i>Blood</i> , 2006 , 108, 3411-3411	2.2
63	Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay.. <i>Blood</i> , 2007 , 110, 5012-5012	2.2
62	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4471-4471	2.2
61	Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1. <i>Blood</i> , 2014 , 124, 3403-3403	2.2
60	Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity. <i>Blood</i> , 2014 , 124, 3414-3414	2.2
59	Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2079-2079	2.2
58	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. <i>Blood</i> , 2014 , 124, 2078-2078	2.2
57	ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis. <i>Blood</i> , 2014 , 124, 2102-2102	2.2

56	Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival. <i>Blood</i> , 2014 , 124, 2012-2012 ^{2,2}	
55	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. <i>Blood</i> , 2014 , 124, 3407-3407	2.2
54	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. <i>Blood</i> , 2014 , 124, 5770-5770	2.2
53	Advanced Osteolytic Lesions (OL), Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM). <i>Blood</i> , 2014 , 124, 3858-3858	2.2
52	Exomic microRNA Profiling of Bone Marrow Aspirate Plasma and Comparison with mRNA Profiles Used in the Clinical Management of Multiple Myeloma. <i>Blood</i> , 2014 , 124, 5681-5681	2.2
51	Mafk Protein Confers Primary Resistance of Myeloma to Proteasome Inhibitors. <i>Blood</i> , 2014 , 124, 2091-2091	
50	Defining Risk of MGUS and AMM Progression to Myeloma By Ig Heavy-Chain FISH. <i>Blood</i> , 2014 , 124, 3408-3408	
49	Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts). <i>Blood</i> , 2015 , 126, 1997-1997	2.2
48	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. <i>Blood</i> , 2015 , 126, 724-724	2.2
47	Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy. <i>Blood</i> , 2015 , 126, 1820-1820	2.2
46	Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma. <i>Blood</i> , 2015 , 126, 2982-2982	2.2
45	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. <i>Blood</i> , 2015 , 126, 4173-4173	
44	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. <i>Blood</i> , 2015 , 126, 3181-3181	2.2
43	Differential ICAM3 Gene Expression Correlates with Susceptibility to Natural Killer Cell-Mediated Lysis in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 2990-2990	2.2
42	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. <i>Blood</i> , 2015 , 126, 3182-3182	2.2
41	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015 , 126, 5395-5395	2.2
40	Identification and Validation of IMiD-14 Model Predictive of IMiD Resistance in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4183-4183	2.2
39	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. <i>Blood</i> , 2015 , 126, 4193-4193	2.2

- 38 47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma. *Blood*, **2015**, 126, 499-499 2.2
- 37 Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma. *Blood*, **2015**, 126, 1777-1777 2.2
- 36 Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. *Blood*, **2016**, 128, 2064-2064 2.2
- 35 Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. *Blood*, **2016**, 128, 357-357 2.2
- 34 Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. *Blood*, **2016**, 128, 4450-4450 2.2
- 33 A Gene Expression Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma.. *Blood*, **2008**, 112, 1667-1667 2.2
- 32 Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma. *Blood*, **2008**, 112, 2715-2715 2.2
- 31 Proteasome Inhibitor, Bortezomib Induces Mesenchymal Stem Cells toward Osteoblast Differentiation through Wnt-Independent Activation of Beta-catenin/TCF Signaling. *Blood*, **2008**, 112, 644-644 2.2
- 30 Bone Morphogenic Protein 6: A Prognostic Factor Expressed by Normal Plasma Cells and Multiple Myeloma Cells Inhibiting Their Proliferation and Angiogenesis Induction. *Blood*, **2008**, 112, 2701-2701 2.2
- 29 Proteomic Profiling of Multiple Myeloma: Correlation of Protein and Gene Expression Data.. *Blood*, **2008**, 112, 1705-1705 2.2
- 28 Bortezomib Induces Osteoblast Differentiation Via Wnt-Independent Activation of Beta-catenin/TCF Signaling. *Blood*, **2008**, 112, 846-846 2.2
- 27 Expression of Myeloma-Specific Markers in Bone Marrow Spicules Using a Novel Immunohistochemical Technique. *Blood*, **2008**, 112, 5152-5152 2.2
- 26 High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2, A Master Regulator of Mirna Maturation and B-Cell Development.. *Blood*, **2009**, 114, 1804-1804 2.2
- 25 Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM). *Blood*, **2010**, 116, 1969-1969 2.2
- 24 Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.. *Blood*, **2010**, 116, 1356-1356 2.2
- 23 Aldehyde Dehydrogenase (ALDH) Vs CD34 for Predicting Engraftment After Autologous Hematopoietic Progenitor Cell (autoHPC) Transplant. *Blood*, **2010**, 116, 4441-4441 2.2
- 22 Inducible Heme Oxygenase 1 (HMOX1) Promotes Osteoblastogenesis, and Inhibits Osteoclastogenesis and Myeloma-Induced Bone Disease. *Blood*, **2011**, 118, 627-627 2.2
- 21 Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease,. *Blood*, **2011**, 118, 3941-3941 2.2

- 20 Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3. *Blood*, **2011**, 118, 3082-3082 2.2
- 19 Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC). *Blood*, **2011**, 118, 298-298 2.2
- 18 Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis. *Blood*, **2011**, 118, 884-884² 2.2
- 17 Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma. *Blood*, **2011**, 118, 2896-2896 2.2
- 16 Myeloma Can Modulate Expanded Natural Killer Cell Function Through Multiple Mechanisms. *Blood*, **2012**, 120, 4020-4020 2.2
- 15 Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up. *Blood*, **2012**, 120, 1458-1458² 2.2
- 14 The Antimalarial Agent Artesunate Overcomes Bortezomib Resistance in Myeloma Cell Lines Through Non-Caspase Mediated Apoptosis. *Blood*, **2012**, 120, 4015-4015 2.2
- 13 Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. *Blood*, **2012**, 120, 2933-2933 2.2
- 12 Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3). *Blood*, **2012**, 120, 195-195 2.2
- 11 FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib. *Blood*, **2012**, 120, 1814-1814 2.2
- 10 Prognostic Significance of DNA/Cig Flow Cytometry Assay in the Era of Novel Therapies in Multiple Myeloma (MM).. *Blood*, **2012**, 120, 2918-2918 2.2
- 9 Renal Function Impairment (creatinine \geq 2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups. *Blood*, **2012**, 120, 1962-1962 2.2
- 8 Hematopoietic Progenitor Cell (HPC) Collection Is Feasible in Previously Transplanted Multiple Myeloma Patients and Plerixafor Improves Collection. *Blood*, **2012**, 120, 4127-4127 2.2
- 7 Lenalidomide Suppression of Multiple Myeloma Cell Proliferation Is Associated with Downregulation of LEF/TCF Activity. *Blood*, **2012**, 120, 5014-5014 2.2
- 6 Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol. *Blood*, **2013**, 122, 3137-3137 2.2
- 5 Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity. *Blood*, **2013**, 122, 5389-5389 2.2
- 4 Healthy Donor Whole Bone Marrow Cells Preconditioned With Myeloma Patient Serum Support Long-Term Survival Of Primary Myeloma and Reveal Altered Microenvironmental Pathways. *Blood*, **2013**, 122, 3118-3118 2.2
- 3 Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis. *Blood*, **2013**, 122, 4432-4432 2.2

- 2 Hemophagocytic relapsed intramedullary plasmacytoma. *International Journal of Hematology*, **2020**, 111, 888-890 2.3
- 1 CA-125 secreting IgG kappa multiple myeloma. *American Journal of Hematology*, **2016**, 91, E457-8 7.1